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1. Introduction
Human Leukocyte Antigen (HLA) is the major histocompatibility complex in humans and it
is critically involved in the rejection of hematopoietic stem cell or organ transplants [1-3] and
in the pathogenesis of numerous autoimmune diseases [4]. Rejection and autoimmunity is
believed to occur because the HLA presents aberrant histocompatibility antigen or public
epitopes that play a key role in self-nonself recognition via various mechanisms including
molecular mimicry and antibody mediated rejection [5-9]. The HLA genomic region on
chromosome 6p21 encodes more than 200 genes including nine classical HLA genes, HLA-A,
-B, -C in the class I region and HLA–DPA1, -DPB1, -DQA1, -DQB1, -DRA, -DRB1 in the class
II region, that are the most polymorphic in the human genome contributing to over 7000 alleles
and numerous HLA haplotypes implicated in disease resistance or susceptibility [10]. There
are also a variety of non-classical HLA genes, such as HLA-DO and HLA-DM [11], HLA-E, -
F, -G, MICA and MICB, which have received less attention in clinical medical research than
the classical HLA genes [12,13].
The determination of the classical HLA alleles by DNA typing techniques over the past thirty
years has assisted with the efficient and rapid HLA matching in transplantation therapy
[2,14,15], research into autoimmunity and HLA related diseases [4,10], population diversity
studies [16-18] and in forensic and paternity testing [19]. HLA gene alleles are also a target for
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pharmacogenomics research into drug hypersensitivity [20], such as the association of HLA-
B*57:01 with hypersensitivity to the antiviral agent abacavir [21] and the association of HLA-
B*15:02 with anticonvulsants in Asian populations [20].
Many variations of the conventional PCR typing method have been used for HLA DNA typing,
such as incorporating restriction fragment polymorphisms [22], single strand conformation
polymorphism [23], sequence specific oligonucleotides (SSOs) [24], sequence specific primers
(SSPs) [25] and sequence based typing (SBT), like the Sanger method [26]. The HLA DNA
typing methods mainly applied today are PCR-SSO, such as the Luminex commercial meth‐
odology [27,28], and SBT by the Sanger method employing capillary sequencing of cloned
chain-termination reactions [26,29]. However, the current, conventional DNA typing methods
cannot readily distinguish between polymorphisms on the same chromosome (cis) or different
chromosomes (trans), thereby creating ambiguities that are difficult, time-consuming and
expensive to resolve. Because we cannot assign a single HLA allele to a particular chromosome
when using these conventional methods in routine HLA-typing, we have to predict the most
probable HLA allele assignment based on the information of allele frequency of a population
or by computation using complex statistical likelihoods. Therefore, in most cases, the HLA
gene haplotype that is the cluster of SNPs within a gene sequence inherited from a single parent
is a statistical prediction rather than a proper empirical determination [30].
The next generation sequencing (NGS) technologies, which are also referred to as second-
generation  sequence  technologies,  are  new  sequencing  developments  [31-33]  that  have
followed  on  from  the  first  generation  sequencing  technologies  of  the  Sanger-Coulson
sequencing  method  using  chain-termination  dideoxynucleotide  sequencing  of  single-
stranded DNA [34]  and  chemical  cleavage  of  double-stranded DNA using  the  Maxam-
Gilbert method [35].  Recent advances in technology and cost effectiveness of NGS point
the way for its implementation and wider use in HLA research and diagnostic settings with
the  generation  of  haplotype  (in-phase)  sequencing  and  a  massive  level  of  parallelism
producing millions of sequencing reads for analysis [36-43]. There are a variety of commer‐
cial NGS platforms currently available for HLA gene amplicon resequencing, such as those
from Roche-454 (454 GS-FLX-Titanium, GS Junior), Applied Biosystems-Agencourt (3730XL,
SOLiD 3), Illumina-Solexa (Genome Analyzer GAII, MiSeq, HiSeq models), Life Technolo‐
gies (Ion Torrent Proton with different high density sequencing Chips),  HeliScope (Heli‐
cos)  and  PacBio  RS  II  (PacBio);  including  three  small  benchtop  sequencers,  the  Roche
Genome Sequencer (GS) Junior, Ion Personal Genome Machine (PGM) sequencer and the
Illumina MiSeq, that are much cheaper than their larger counterparts and that provide faster
turnover rates, but a more limited data throughput [31,44-46].
Recently, the performances of the three commercially available benchtop sequencers were
compared against each other directly by different investigators comparing the sequencing of
bacterial genomes [45-47]. There were large differences obtained from the three platforms in
cost, sequence capacity and in performance outcomes of genome depth, stability of coverage
and read lengths and quality, due in part to their different sequencing methods. The Roche GS
Junior was of intermediate price with the lowest sequencing capacity of >6 Mb per run and a
run time of 8 h, but the highest cost per run because of expensive reagents. Its sequencing is
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dependent on using the pyrosequencing technique, measuring the fluorescent light emitted
when fluorophore-labeled dNTPs are added to sample DNA templates during the polymerase
reaction [31,32]. The MiSeq was the most expensive instrument with the highest throughput
at 1.5-2 Gb and a run time of 27 h. The running cost was 60 times cheaper than the Roche GS
Junior. The MiSeq uses reversible terminator chemistry for sequencing in a cyclic method that
involves fluorophore-labeled nucleotide incorporation, fluorescence imaging and cleavage
[31,48]. The Ion PGM was the cheapest instrument with a throughput of 100 Mb using the 316
Chip, and 1 Gb using the 318 Chip, and a run time of 2-3 h. The running cost was 8 to 50 times
cheaper than the Roche GS Junior depending on which Chip was purchased. The Ion PGM
uses semi-conductor technology and ion-sensitive transistors to sequence DNA using only
DNA polymerase and natural nucleotides in a sequencing-by-synthesis approach, with each
polymerisation event resulting in pH and voltage changes identified by electronic sensors [33].
Therefore, the Ion PGM is the only “non-light” sequencer currently available in the market
place.
Most pre-sequencing workflows for the benchtop sequencers and the other machines require
DNA template fragmentation and library preparation where the fragments are labeled in vitro
with oligonucleotide tags and adapters using commercial kits such as NimbleGen, Sure Select
and other systems in order to be captured by beads or probes in preparation for clonal
amplification of single stranded DNA fragments [31]. The labeling of DNA libraries with
barcode sample tags, such as the multiplex identifier (MID) for Roche/454 sequencing, allows
the libraries to be pooled to maximize the sequence output as a multiplex amplicon sequencing
step for each sequencing run [49,50]. After construction of the template libraries, the DNA
fragments are clonally amplified by emulsion PCR [51,52] or by solid phase PCR using primers
attached to a solid surface [53] in order to generate sufficient single stranded DNA molecules
and detectable signal for generating sequencing data [31]. Apart from selecting a suitable
sequencing machine, NGS also provides challenges in analyzing and interpreting complex
HLA genomic data from the millions of sequencing reads generated from the next-generation
sequencers, which are different to those generated from traditional sequencers, and other HLA
DNA typing methods and platforms.
We have described a new HLA DNA typing method, called Super high-resolution Single
molecule - Sequence Based Typing (SS-SBT), that employs NGS and the Roche GS Junior [54]
and the Ion PGM [55] massively parallel sequencing bench-top platforms (Figure 1). The SS-
SBT method allows sequencing of the entire HLA gene region (promoter/enhancer, 5’UT,
exons, introns, 3’UT) to detect new alleles and null alleles and solves the problem of phase
ambiguity by using bioinformatics and computing for accurate phase alignments, after long-
range PCR and sequencing clonally amplified single DNA molecules [42, 56].
This chapter updates our progress with the SS-SBT method [42] and describes some of the tasks
required to identify the polymorphisms and other variants generated by NGS for SNP
haplotyping from different classical HLA loci of individuals such as tissue donors and
recipients in a relatively simple and economical way.
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1.1. Aims of chapter
Here we describe and examine our latest modifications to the SS-SBT method for six-classical
class I and class II HLA loci (HLA-A, -B, -C, -DPB1, -DQB1 and -DRB1) at a super-high
resolution (formerly known as the 8-digit level of resolution) and three non classical class II
HLA loci HLA-DRB3, -DRB4 and –DRB5 at high resolution using single DNA molecules to
solve the ambiguity problem by undertaking:
1. Specific amplification of the entire gene sequence.
2. Comparisons between two different NGS platforms, the Roche GS Junior and Ion PGM.
3. Comparisons between different DNA typing software for in phase sequence analysis and
validation of the huge amounts of NGS data.
4. Comparison of workflow differences in the construction of single gene and multiplex gene
sequencing template libraries for 11 HLA class I and class II loci.
5. Application of the SS-SBT method including PCR multiplexing for the construction of
template libraries for more efficient sequencing runs.
2. Materials and methods
2.1. HLA allele nomenclature and definition of super-high resolution
HLA genotyped alleles can be assigned at different levels of detail according to a recommend‐
ed, standardized nomenclature [57]. Designations begin with HLA- as the prefix for an HLA
gene and the locus name, followed by a separator * and then one or more two-digit numbers
separated by colons (field separators) that specify the allele. The first two digits specify a group
of alleles (first order, field one or a low resolution level). The third and fourth digits specify a
non- synonymous allele (second order, field two or an intermediate resolution level). Digits
five and six denote any synonymous mutations within the coding frame of the gene (third
order, field three or a high resolution level). The seventh and eighth digits distinguish
mutations outside the coding region (fourth order, field four or a super high resolution level).
A ninth digit usually specifies an expression level or other non-genomic data and it is desig‐
nated by a letter such as A (‘Aberrant’ expression), C (present in the 'Cytoplasm' but not on
the cell surface), L (‘Low’ cell surface expression), N (‘Null’ alleles), Q (‘Questionable’ expres‐
sion) or S (expressed as a soluble 'Secreted' molecule but is not present on the cell surface).
Thus, a completely described allele may be up to 9 digits long. An example of an eight-digit
or a super high resolution of an HLA-A allele that includes sequence variation within the
introns or 5’/3’ extremities of the gene is HLA-A*01:01:01:01.
2.2. DNA samples
One hundred genomic DNA samples were obtained from Japanese subjects for this study on
PCR amplification and NGS of HLA genes. We obtained written consent from each individual
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and ethical approval from Tokai University School of Medicine where the research was
performed. The DNA samples were isolated from the peripheral white blood cells using the
QIAamp DNA Blood Mini Kit (QIAGEN, Germany). The HLA class I and class II gene alleles
for nine samples (TU1 to TU8 and TU10) had been previously assigned to the field 2 allelic
level of resolution (formerly known as 4-digit typing) [57] by the Luminex method [27,58] and
LABType SSO kits (One Lambda, CA).
2.3. DNA extraction
Genomic  DNA  samples  were  isolated  from  the  peripheral  white  blood  cells  using  the
QIAamp DNA Blood Mini Kit (Qiagen). The purity of the genomic DNA for each sample
was determined by measuring the absorbance at 260 and 280 nm, with the A260/A280 values
being in the range of 1.5-1.9, and the concentration of the DNA was adjusted to 10-20 ng/μl
using PicoGreen assay (Life Technologies, CA).
Figure 1. The benchtop sequencers, Ion PGM from Ion Torrent and GS Junior from Roche/454
2.4. HLA DNA typing of genomic DNA samples by the Luminex method
The samples were typed at HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 using the Luminex
method [27,28,58] and reagents supplied by the LABType SSO kits (One Lambda). An outline
of the workflow for the Luminex method is shown in Figure 2.
2.5. HLA DNA typing of genomic DNA samples by SBT and the Sanger sequencing method
The DNA samples were typed at HLA-A, -B and -C (exons 2, 3 and 4) and -DRB1 (exon 2) using
AlleleSEQR HLA-SBT Reagents (Abbott Laboratories, Abbott Park, IL). To confirm that the
HLA alleles from both chromosomes were amplified with a 1:1 ratio and to validate newly
discovered SNPs and indels, the nucleotide sequences of the PCR products were also directly
sequenced by using the Sanger method and the ABI3130 genetic analyzer (Life Technologies,
CA) in accordance with the protocol of the Big Dye terminator method (Life Technologies).
The sequence-generated chromatogram data was analyzed by the Sequencher ver.4.10 DNA
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sequence assembly software (Gene Code Co., MI). Sequence data were also analyzed using the
assign-atf software (Conexio Genomics, Australia, [59]). An outline of the workflow for the
Sanger sequencing method is shown in Figure 2.
2.6. SS-SBT by NGS
We used two different benchtop NGS platforms (Figure 1); massively parallel pyrosequencing
with the Roche GS Junior Bench Top system [54] and massively parallel semiconductor
sequencing with the Ion Personal Genome Machine (PGM) system [55]. A general review of
the NGS workflows used for the Roche 450 system is presented by Margulies et al. [51], Metzger
[31] and Erlich [41] and for the Ions PGM/Torrents system by Rothberg et al. [33].
For SS-SBT, we used a five-step workflow for HLA DNA genotyping and haplotyping for both
the Roche GS Junior Bench Top system and the Ions PGM (Figure 2). These steps were LR-
PCR, amplicon library construction, template preparation by emulsion (em) PCR, NGS run
and HLA DNA data analysis. The first and last steps were essentially the same for both
platforms, whereas steps 2 to 4 were platform specific. Two different sequencing runs, a single
gene-sequencing run (SGSR) or a multiplex gene sequencing run (MGSR) were performed for
the different HLA gene loci. SGSR was performed for only a single gene locus per run, whereas
MGSR was performed at the same time for all of the HLA gene loci, whereby all of the LR-
PCR amplicons were pooled together to construct the template libraries required for the
sequencing platforms.
2.6.1. Step 1: LR-PCR
Single LR-PCR
We developed and used LR-PCR primers for eleven HLA loci, A, B, C, DRB1, DRB3, DRB4,
DRB5 (DRB3/4/5), DQA1, DQB1, DPA1 and DPB1 [42, 56]. For amplification of the HLA-DRB1,
group-specific primers were employed to prevent concomitant amplification of DRB1-like
genes, such as DRB3, DRB4, DRB5 and DRB pseudogenes including DRB2, DRB6, DRB8 and
DRB9. Others have reported different LR-PCR primer sets for some of the same HLA genes
[40,43].
Pooling the LR-PCR amplicons
Amplicons from all class I and class II loci for each individual were pooled in equal amounts
to yield 2-3 μg per pool of a single sample.
2.6.2. Steps 2 to 4: Amplicon library construction, emPCR and NGS
Both NGS platforms require the preparation of a fragmented template library of the PCR
products and further clonal amplification of the templates by emPCR for sequencing of singled
stranded DNA and detection of base-called signals (Figure 2).
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Figure 2. Workflow and time (hours) taken for each HLA genotyping step using the SS-SBT method by NGS with the
Ion PGM or Roche GS Junior sequencers, by SBT using the Sanger sequencing method or by PCR-SSO using the Lumi‐
nex method. The times are for typing five HLA loci using four DNA samples
2.6.2.1. Workflow for Roche GS Junior Bench Top system
Titanium libraries of single-stranded template DNA fragments were prepared for emPCR
and  sequencing  using  a  GS  FLX  Titanium  Rapid  Library  Preparation  kit  (cat  no.
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05608228001, 454 Life Sciences, Schweiz, CA) together with the GS Titanium Rapid Library
MID Adaptors Kit (cat no. 05619211001, 454 Life Sciences) that permits the preparation of
up to 12 individually MID labeled libraries per kit [60]. The workflow with the prepara‐
tion  kit  involved  fragmenting  the  LR-PCR  amplicons  by  nebulization  using  disposable
nebulisers, repairing fragment ends in a thermocycler reaction with T4 polymerase and Taq
polymerase, adding adaptors such as the fusion A and B capture/sequence adapters and
MID tags to the fragmented DNA by ligation with ligase and then linking the fragments
of 100 bp or larger to the AMPure paramagnetic beads (Beckman Coulter Genomics, MA)
with a selective binding buffer. Small fragments, primers and nucleotides were removed
from the  magnetic  beads  by  washing  them with  70% ethanol.  Each  single-strand DNA
library was eluted from the beads with water or a Tris-acetate buffer, pH 8.
A MID adaptor was substituted for the adaptor provided in the GS FLX Titanium Rapid
Library Preparation kit during the preparation of a library from a PCR DNA sample. The
MID adaptor was ligated to each fragmented sequence of a library to provide a recogniza‐
ble sequence tag at  the beginning of  each read.  In this  way,  multiple libraries prepared
with different MIDs can be sequenced together allowing the data analysis software to assign
each read to the correct library and therefore a particular sample.
The libraries were quantified in 96-well format using the Fluoroskan Ascent CF Ver. 2.6
software (Thermo Fisher Scientific, DE) to detect the fluorescence in a PicoGreen assay (Life
Technologies). The library size for each sample was measured by an Agilent 2100 Bioanalyzer
using an Agilent High Sensitivity DNA Kit (Agilent Technologies, CA) and pooled with the
other libraries at equimolar concentrations to create a multiplexed library.
The  multiplexed  libraries  were  clonally  amplified  by  emPCR in  order  to  produce  hun‐
dreds of thousands or millions of copies of the same template sequence so that sufficient
signal would be generated to be easily detected and recorded by the sequencing system.
For  preparation  of  emulsion  beads,  the  single-stranded DNA fragmented libraries  were
added to the capture beads A and B, emulsified with oil and then amplified for at least 6
hours with an enzyme and reaction mix provided in the GS Junior Titanium emPCR Kit
(Lib-L). An emulsion of PCR reagents in microreactors was prepared by adding beads A
and B  to  the  PCR reaction  mix  (1X  amplification  mix,  Amplification  Primers,  0.15U/ml
Platinum Taq (Life Technologies), and emulsion oil and mixing vigorously using a Tissue
Lyser (Qiagen, Germany).
The emulsion PCR of the library templates was carried out in an ABI 9700 (Life Technolo‐
gies)  thermocycler  using  the  following  cycling  conditions:  hotstart  activation  for  4  mi‐
nutes at 94°C, 50 cycles of 94°C for 30 seconds, 58°C for 4.5 minutes, 68°C for 30 seconds.
Sequencing primers were added to the mixture of beads and annealing buffer and annealed
to the template using the following thermocycler conditions: 65°C for 5 minutes, and kept
on ice for 2 minutes..
After  emPCR,  the  emulsion  was  broken  by  isopropanol,  the  beads  carrying  the  single-
stranded DNA templates were enriched with primers A and B, counted, and 0.5 million
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beads deposited along with enzymes and buffer into a single loading port of a GS Junior
Titanium PicoTiterPlate (PTP) (Cat. No 05 996 619 001, 454 Life Sciences, Carlsbad, CA) to
obtain sequence reads by pyrosequencing using the Roche GS Junior system. Packing beads,
sample beads and enzyme beads were applied to the PTP as  per  manufacturer  instruc‐
tions. The GS Junior Titanium PicoTiterPlate permits only a single sequencing run per PTP.
During  sequencing,  nucleotides  flowed across  the  PicoTiterPlate  in  a  fixed order  and a
cooled  CCD  camera  recorded  the  amount  of  light  generated  by  the  pyrosequencing
reactions. The images from the CCD camera were then converted to sequence data by the
instrument’s software.  Bi-directional sequencing for the fragments was achieved because
the single strands captured by the A and B beads allow both forward and reverse reads to
be identified.
After the DNA sequencing run by the Roche GS Junior Bench Top system, data analysis
such  as  image  processing,  signal  correction  and  base-calling,  binning,  trimming  and
mapping  of  the  sequence  reads  and  assignment  of  HLA  alleles  were  carried  out  in
accordance with our previous publication [42]. Image processing, signal correction and base-
calling  were  performed by  the  GS  Run  Processor  Ver.  2.5  (454  Life  Sciences)  with  full
processing for shotgun or filter analysis. Quality-filter sequence reads that were passed by
the assembler software (single sff file) were binned on the basis of the MID labels into 10
separate sequence sff  files using the sfffile software (454 Life Sciences).  These files were
further quality trimmed to remove poor sequence at the end of the reads with quality values
(QVs) of less than 20.
2.6.2.2. Workflow for Ion PGM system
Barcoded-library DNAs were prepared from PCR amplicons with an Ion Xpress Plus Fragment
Library Kit and Ion Xpress Barcode Adaptors 1-16 Kit according to the manufacture’s protocol
for 200 base-read sequencing (Life Technologies). One hundred nanograms of the HLA pooled
amplicon products from four individuals were used for the preparation of each DNA library.
Each DNA library was clonally amplified by eight cycles of PCR. The DNA size for each library
was measured by an Agilent 2100 Expert Bioanalyzer using the Agilent High Sensitivity DNA
Kit (Agilent Technologies) and the concentration of each library was measured with the Ion
Library Quantitation Kit using the 7500 Real-Time PCR System (Life Technologies). Each
barcoded-library was mixed at equimolar concentrations then diluted according to the
manufacture’s recommendation. emPCR was performed using the resulting multiplexed
library with the Ion Xpress Template 200 Kit on an ABI 9700 (Life Technologies) with the
following cycling parameters: primary denaturation 94◦C/6 min, followed by 40 cycles for
94◦C/30 s, 58◦C/30 s and 72◦C/90 s, and 10 cycles for 94◦C/30 s and 68◦C/6 min. After the
emulsion was broken with 1-butanol, a magnetic-bead-based process according to the
manufacture’s recommendation enriched the beads carrying the single-stranded DNA
templates. Sequencing was performed using the Ion Sequencing 200 Kit and Ion 316 chip with
a flow number of 440 for 200 base-read [61].
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Ion Torrent uses a pH change (release and detection of a proton) to detect the incorporation
of a base into the growing DNA strand rather than a flash of light, as used in the 454 Sequencing
System [33].
In the case of the Ion PGM DNA sequencing system, the raw data processing and base-calling,
trimming and output of quality-filter reads that were binned on the basis of the Ion Xpress
Barcodes into 10 separate sequence sff files were all performed by the Torrent Suite 1.5.1 (Life
Technologies) with full processing for shotgun analysis. These files were further quality
trimmed to remove poor sequence at the end of the reads with QVs of less than 10.
2.6.2.3. Sequencing parameters, variables and definitions
The NGS methodology generates a number of sequencing parameters, variables and errors
that need to be defined and noted.
A sequencing read is a contiguous length of nucleotide bases that is generated using a
sequencing machine. The full set of aligned reads (coverage) reveals the entire genomic
sequence in the DNA sample selected for sequencing.
Both the NGS methods described here are designed to generate hundreds of thousands to
millions of short (100 to 800 bp) contiguous reads of low to high quality. Intrinsic quality
measures or filters are automatically built into the sequencing analysis software to recognize
and measure or statistically predict quality values (QV or Q) and remove incorrect repetitive
sequence, indels, low-quality sequence at the beginning and end of runs (end clipping) and
recognize accurate consensus sequences [62,63].
Generally, the QVs or Q’s are based on estimated Phred quality scores [64] so that a quality
score of 10 represents a 1 in 10 probability of an incorrect base call or 90% base call accuracy,
20 represents a 1 in 100 probability of an incorrect base call or 99% base call accuracy, 30
represents a 1 in 1000 probability of an incorrect base call or 99.9% base call accuracy, 40
represents a 1 in 10000 probability of an incorrect base call or 99.99% base call accuracy, and
so on.
QV scores are clearly valuable because they can reveal how much of the data from a given run
is usable in a resequencing or assembly experiment. Sequencing data with lower quality scores
can result in a significant portion of the reads being unusable, resulting in wasted time and
expense. A QV of ≥ 20 is usually considered a satisfactory cut-off score for base calling accuracy.
The QV and Q reads from the GS Junior and the Ion PGM are slightly different from each other
and not directly comparable, with some studies showing the GS Junior overestimates the base-
calling accuracy while the Ion PGM underestimates the base-call accuracy [45,65-67].
Read depth is the number of individual sequence reads that align to a particular nucleotide
position [40]. The average read depth (coverage, redundancy or depth) is the number of
average reads representing or covering a given nucleotide in the reconstructed sequence, often
calculated as N x L/G where G is the original length of the genome sequence, N is the number
of reads and L is the average read length. Thus, for a 1000 bp sequence G reconstructed from
10 reads N with and average length of 200 nucleotides per read L, there is a 2x coverage or
redundancy. However, reads are not distributed evenly over an entire genome and many bases
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will be covered by fewer reads than the average coverage, while other bases will be covered
by more reads than average [68].
Another important variable to consider, particularly for HLA typing with NGS is the allelic
balance [40] or the ratio of the average depth [42], which is the relative number of reads
originating from each of the two alleles of each locus. This variable is important to monitor in
order to prevent allele drop-out. Allelic imbalance is usually not a sequencing problem, but
most often is due to poor genomic PCR primer design where a set of primers favours the
amplification of one haplotype over the other.
Sequence accuracy to estimate the quality of a sequencing run was estimated by including
internal control DNA beads of known sequence with each run.
2.6.3. Step 5: DNA sequence data analysis and HLA assignments
The trimmed and MID or barcoded binned sequences were mapped as perfectly matched
parameters using the GS Reference Mapper Ver. 2.5 (Life Technologies). Reference sequences
used for mapping of the sequence reads were selected by nucleotide similarity searches with
HLA allele sequences in the IMGT-HLA database using the BLAT program [69]. If a reference
sequence covering the entire gene region was not available, we converted the sff files to ace
files and constructed a new virtual sequence by de novo assembly using the sequencher Ver.
4.10 DNA sequence assembly software (Gene Code Co, Ann Arbor, MI), and used it as a
reference sequence.
Three different automated NGS data processing systems, the Sequence Alignment Based
Assigning Software (SEABASS) (an in house development of Tokai University, Isehara),
Omixon Target (Omixon, [70]) and Assign MPS v1 (Conexio, [59]) were also assessed and
compared for in phase sequence alignment of HLA genes and for allele assignment at the 8-
digit level. The three programs were designed to provide software or a suite of software tools
for analyzing targeted sequencing data from the next generation sequencing platforms, Roche
454, Ion Torrent and Illumina. The HLA edition of the Omixon Target can be obtained for use
with MacOSX or Windows as a credit-based or annual based license fee. Conexio software for
Windows can be purchased outright, whereas SEABASS is an in house development for Linux
and is not available commercially at this time.
3. Results
3.1. HLA typing by Sanger SBT, the Luminex method or SS-SBT by NGS
Ten genomic samples (TU1-TU10) were genotyped at six HLA loci (HLA-A, -B, -C, -DRB1, -
DQB1 and –DPB1) by three different typing methods, the Luminex, the Sanger SBT and the
NGS SS-SBT method. At least one or more pairs of unresolved alleles were detected in the
samples by the SBT and/or Luminex methods, whereas all the samples were easily resolved at
least to the 4-digit level by the SS-SBT typing method (see the Tables and Supplementary Tables
in the paper by Shiina et al [42]). Table 1 shows an example of the DNA typing results obtained
for the HLA-C locus by the Luminex, SBT or SS-SBT methods as previously reported.
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HLA-C typing by Luminex method
DNA Sample ID Allele 1 Allele 2 Number of ambiguitiesAllele 1 Allele 2
TU1 C*01:02/07/11/+ C*03:03/11/12/+ 18 17
TU2 C*01:02/07/11/+ C*03:04/06/09/+ 18 23
TU3 C*03:03/04/06/+ C*07:02/10/13/+ 40 29
TU4 C*03:03/04/06/+ C*14:03/10 41 2
TU5 C*03:02/04/05/+ C*07:02/10/13/+ 40 29
TU6 C*03:03/04/06/+ C*14:03/10 41 2
TU7 C*01:02/07/11/+ C*07:02/32/38/+ 17 25
TU8 C*08:03/06/14 C*14:03 3 0
TU9 C*08:01/08/20/+ C*15:02/03/10/+ 7 5
TU10 C*07:02/10/19/+ C*15:02/03/07/+ 27 7
HLA-C typing by SBT method
Allele 1 Allele 2 Ambiguities (Allele 1 and Allele 2)
TU1 C*01:02/22/51 C*03:03/04/20/+ 9
TU2 C*01:02/22/31/+ C*03:04/28/64/+ 8
TU3 C*03:03/04/13/+ C*07:02/10/50/+ 18
TU4 C*03:03/04/20 C*14:03/10 4
TU5 C*03:04/32/35/+ C*07:02/10/29/+ 15
TU6 C*03:03/04/20 C*14:03/10 4
TU7 C*01:02/17/22 C*07:02/37/39/+ 10
TU8 C*08:03:01 C*14:03 0
TU9 C*08:01/10/22 C*15:02/17 3
TU10 C*07:02/19/39/+ C*15:02/03/07/+ 8
HLA-C typing by SS-SBT using Roche GS Junior
Allele 1 Allele 2 Ambiguities
TU1 C*01:02:01 C*03:03:01 0
TU2 C*01:02:01 C*03:04:01:02 0
TU3 C*03:03:01 C*07:02:01:03 0
TU4 C*03:03:01 C*14:03 0
TU5 C*03:04:01:02 C*07:02:01:(04) 0
TU6 C*03:03:01 C*14:03 0
TU7 C*01:02:01 C*07:02:01:(05) 0
TU8 C*08:03:01 C*14:03 0
TU9 C*08:01:01 C*15:02:01 0
TU10 C*07:02:01:01 C*15:02:01 0
Table 1. Results of HLA DNA typing for the HLA-C locus by the Luminex, SBT or SS-SBT methods. The / is possible
ambiguity, + is more than the possible ambiguities indicated by /, Parenthesis and bold letters indicate tentative allele
names, not yet officially approved by the WHO Nomenclature Committee.
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Figure 3 shows how the SS-SBT NGS typing method resolves the phase ambiguity at the HLA-
DRB1 locus of a sample that the Luminex beads and other conventional typing methods were
not able to resolve. Essentially, the Luminex bead method analyzed the mixture of the PCR
products amplified from the paternal and maternal chromosomes and could not distinguish
between HLA-DRB1*15:01/DRB1*04:05 on Sample “A” and HLA-DRB1*15:02/DRB1*04:10 on
Sample “B”, and therefore, resulting in ambiguity. On the other hand, in the SS-SBT method
the sequenced PCR products were each amplified from a single DNA molecule (clonal
amplification method by emulsion PCR), which helps to determine whether each polymor‐
phism is paternal or maternal, thus resolving phase ambiguity. In the case shown in Figure 3,
the sample was typed as DRB1*15:02/DRB1*04:10 on Sample “B”.
Figure 3. SS-SBT resolves phase ambiguity, which is an inherent problem of the Luminex beads method and other
conventional methods
3.2. HLA typing by SS-SBT using two different NGS benchtop platforms
3.2.1. LR-PCR
3.2.1.1. Single LR-PCR
Long-range PCR (LR-PCR) was developed to amplify eleven HLA genes (HLA-A, -C, -B, -
DRB1, -DQA1, -DQB1, -DPA1, -DPB1, -DRB3, -DRB4 and –DRB5) that are known to be highly
polymorphic. PCR primers were designed to avoid annealing to any known polymorphic sites
and to amplify regions spanning from the 5’ promoter to the 3’UTR region of the HLA genes
in either a single amplification reaction or as two separately divided amplifications that could
be easily merged when sequenced.
The PCR primer sets for the HLA-A, -B and -C genes were designed to amplify their sequences
from the 5’-enhancer-promoter region to the 3’UTR with an amplicon size of about 5 kb. PCR
primer sets were designed for HLA-DQA1, -DQB1, and -DPA1 to amplify sequences from the
5’- enhancer-promoter region to the 3’UTR with amplicon sizes of about 7 to 10 kb bases.
Because the gene sizes for HLA-DRB1 and -DPB1 were too long to successfully amplify the
whole gene in a single reaction, we divided the amplification of these genes into two parts.
One PCR primer pair was designed to amplify the 5’-enhancer-promoter region to exon 2 and
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the other primer pair was designed to amplify exon 2 to the 3’UTR, resulting in amplicon sizes
of about 6 to 11 kb and 5 to 7 kb, respectively (Figure 4). The DRB1 locus produced different
amplicon sizes because of allelic differences in the length of its introns.
LR-PCR  methods  were  also  designed  and  tested  to  amplify  HLA-DRB3,  -DRB4  and  -
DRB5 (DRB3/4/5) from intron 1 to exon 6 (3’UTR) with the product size of 5.6 kb for DRB3,
5.1  kb  for  DRB4  and  4.7  kb  for  DRB5.  The  DRB3/4/5  specific  primer  sets  successfully
amplified the HLA-DRB3, -DRB4 and -DRB5 genes from 19 positive genomic DNA samples
(TU1 to TU8, TU10 to TU17 and TU20 to TU22) with PCR products varying in size between
4.7 kb to 5.6 kb (Figure 4, [56]).
Although some LR-PCR methods are known to produce low frequency extra amplification of
pseudogenes, as previously reported [43], our LR-PCR methods generally produced specific
amplicons of targeted genes with little or no evidence of extra sequences (Figure 4). In addition,
allelic imbalance for all the LR-PCR methods was minimal as judged by the sequencing results
with allelic ratios ranging on average between 0.6 and 1.6 in heterozygous samples.
3.2.1.2. Pooling LR-PCR products for library construction
In order to expedite the number of samples and HLA loci required for NGS, the single LR-PCR
products were pooled in equimolar amounts to produce a single multiplex (up to 13 PCR
products) for the construction of a multiplexed, barcoded sample library. Figure 5 shows an
example of an electrophoretogram of the pooled PCR amplicons from the HLA-A, -B, -C and
-DRB1 genes.
3.2.2. Roche GS Junior NGS system
3.2.2.1. Library preparations using different gene loci and sample numbers
Initially,  we  applied  an  individual  tagging  per  gene  amplicon  method  for  SGSR  by
preparing a tagged library for each of the ten individual samples with the aim of sequenc‐
ing one  HLA locus  at  a  time [42].  Thus,  ten  libraries  were  constructed from each PCR
amplicon of a particular HLA locus, with each library representing an HLA gene with ten
tagged individual  samples.  The  ten  individual  MID-labelled  ssDNA libraries  were  then
combined  into  a  single  tube  for  clonal  emPCR  and  sequencing.  In  this  way,  we  per‐
formed  a  single  sequencing  run  for  each  HLA  locus  represented  by  ten  MID  labelled
individuals, one locus at a time. For example, Run 1 was HLA-A with samples one to ten;
Run 2 was HLA-B with samples one to ten, Run 3 was HLA-B with samples one to ten,
and so on until we finished Run 13, our last run, Run 13, representing the 13th LR-PCR
amplicon we had amplified from the 11 HLA gene loci that we had chosen to analyze.
Later, we changed from SGSR to an individual tagging and gene-pooling method for MGSR
in order to markedly reduce the number of required sequencing runs. In this approach, we
first pooled the PCR amplicons obtained from the eleven separate HLA genes (HLA-A, -
B, -C, -DQA1, -DQB1, -DPA1, -DRB1 (part a and b), -DPB1 (part a and b), -DRB3, -DRB4
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and -DRB5 of  each individual  at  equimolar  concentrations and then prepared the MID-
labeled NGS libraries using the pooled amplicons from each individual. In this way, a single
Figure 4. Agarose gel electrophoresis of LR-PCR products obtained from 10 to 19 unrelated genomic DNA samples
using locus-specific primers for 11 HLA genes. The individual LR-PCR amplicons were used for SGSR or were combined
into a single pooled mix for MGSR. Figure adapted from [42] and [56]
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sequencing run was performed for all eleven HLA loci and for a multiple number of MID-
labelled individuals or DNA samples. This was possible because the sequencing adapters
specifically  identified  and  grouped  the  gene  loci,  whereas  the  MID  tags  identified  the
individual samples.  Figure 5 shows an electrophoretogram of pooled LR-PCR amplicons
amplified  from samples  with  known DR sub-types  in  parenthesis  such that  lane  1  is  a
heterozygous sample of DR6 and DR9, lane 2 is heterozygote of DR2 and DR6, lane 3 is a
heterozygote of DR2 and DR4, lane 4 is a heterozygote of DR3 and DR8 and lane 5 is a
heterozygote of DR1 and DR7. Consequently, the PCR product from the DRB1 gene varies
in size depending on the DR sub-type and associated HLA-DRB1 allele so that it is 5.1 kb
(orange) and 5.2 kb (blue) in lane 1, 5.2 kb (blue) and 5.6 kb (green) in lane 2, 5.6 kb (green)
and 6.2 kb (purple) in lane 3, 5.2 kb (blue) in lane 4 and 5.1 kb (orange) and 5.2 kb (blue)
in lane 5.
3.2.2.2. Sequencing multiplex libraries prepared for SGSR
Table 2 shows the number of draft sequences or reads (sequences passing a quality control
criteria after base calling), generated by the Roche GS Junior Bench Top system for HLA-
C  in  ten  samples  using  multiplex  libraries  prepared  for  SGSR.  The  results  for  the  se‐
quence information about HLA-C were reported previously by Shiina et al [42] and Ozaki
et al [56] as part of the data obtained in their NGS analysis of the eleven HLA loci.
DNA MID Draft Draft Read Avg Read Edited Reads No. Mapping
Sample type Read Bases (bp) Length (bp) (% of Draft Bases (bp)
ID Numbers Reads) post edit
TU1 MID1 7,873 3,213,949 408.2 5,075 (64.5%) 1,640,715
TU2 MID2 17,926 7,472,332 416.8 12,002 (67.0%) 4,003,792
TU3 MID3 8,211 3,326,703 405.2 5,553 (67.6%) 1,678,658
TU4 MID4 18,617 7,782,001 422.5 12,600 (67.7%) 4,223,267
TU5 MID5 12,432 5,185,865 417.1 8,318 (66.9%) 2,617,187
TU6 MID6 8,292 3,468,588 418.3 5,784 (69.8%) 1,982,456
TU7 MID7 10,900 4,503,252 413.1 7,042 (64.6%) 2,181,140
TU8 MID8 11,507 4,793,240 416.5 7,801 (67.8%) 2,554,949
TU9 MID9 12,082 4,995,156 413.4 8,101 (67.1%) 2,709,149
TU10 MID10 17,674 7,415,292 419.6 12,929 (73.2%) 3,968,608
Total 125,514 52,156,378 416.2 85,205 (67.9%) 27,559,921
Table 2. Sequence read information obtained by the Roche GS Junior for HLA-C.
Draft read numbers for eight genes, HLA-A, -C, -B, -DRB1, -DQA1, -DQB1, -DPA1 and -DPB1,
were 1,015,526 sequence reads in total for 10 samples per locus with a range of reads between
49,048 in HLA-DQA1 and 153,610 sequence reads in exon 2 to 3′UTR of HLA-DRB1 [42]. These
were high quality reads with QV ≥ 20 and an average QV of 30.4 ranging between 28.6 and
32.4. The draft read bases for eight genes, HLA-A, -C, -B, -DRB1, -DQA1, -DQB1, -DPA1, -
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DPB1, were 412,956,301 bp in total with a range between 18,077,833 bp in HLA-DQA1 and
65,384,530 bp in exon 2 to 3’UTR of HLA-DRB1 [42]. There was an overall average sequence
length of 414.2 bp, ranging from 321.8 bp in intron 1 to 3’UTR of HLA-DPB1 to 441bp in HLA-
DPA1. Of the draft reads, excluding error reads such as artificial insertion or deletion (indel)
and nucleotide substitutions, 49.7%–75.4% matched perfectly with HLA allele sequences
released from the IMGT-HLA database or our newly constructed virtual reference sequences.
Therefore, the sequence reads had high quality and sufficient sequence volume for further
HLA DNA genotyping and haplotyping analysis.
The HLA-DRB3, -DRB4 and -DRB5 (DRB3/4/5) gene loci were each sequenced separately by
the Roche GS Junior Bench Top system using 19 samples and two separate multiplex libraries.
After the sequencing run for each gene, a total of 147,269 sequence reads were provided for
mapping and allele assignment of DRB3/4/5. The sequence reads were high quality reads
(QV≥20) with an average QV of 30.9 ranging between 28.6 and 32.4. The draft read bases in
total were 62.3 Mb in DRB3/4/5, with an overall average sequence length of 423.2 bp, ranging
from 361 bp to 445.6 bp. This data suggested that the sequence reads had sufficient high quality
and sequence volume for further HLA DNA genotyping and haplotyping analysis.
Figure 5. (A) Agarose gel electrophoresis of pooled LR-PCR amplicons of HLA-A (green), -B (red), -C (yellow) and -
DRB1 (purple, green, blue and orange) used for MGRS. The lanes labeled M are bands of the 1 kb DNA size marker
ladder. (B) Schematic of the expected PCR product band patterns and sizes seen in the PCR multiplex amplified from
samples with different DR subtypes
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3.2.2.3. HLA SS-SBT DNA typing
HLA typing was applied to 10 genomic DNA samples (TU1-TU10) all of which gave more than
one pair of unresolved alleles when defined by the SBT and/or Luminex methods (Table 1 and
Table 3). In comparison, the pyrosequencing reads using Roche GS Junior system matched
perfectly with the HLA allele sequences previously deposited in the IMGT-HLA database or
against the virtual allele sequences constructed by de novo assembly as reference sequences.
HLA allele sequences were determined at the 8-digit level in both phases in all samples of
HLA-C (Table 1) and –DRB1 (Table 3) as well as HLA-A, -B, and -DQB1. Ambiguous alleles
were resolved by in phase (haplotype) sequencing through the heterozygous positions thereby
eliminating any doubt about possible alternative allele combinations (Figure 3). Cloning and
Sanger sequencing validated the accuracy of the sequencing results by NGS (data not shown).
DNA sample ID Sanger-SBTAllele 1 Allele 2
TU1 DRB1*09:01/06 DRB1*15:01/02
TU2 DRB1*09:01/06 DRB1*14:05/44
TU3 DRB1*01:01/17/20 DRB1*14:05/44/100
TU4 DRB1*04:10/11 DRB1*14:01/32/54
TU5 DRB1*09:01:02 DRB1*13:02:01
TU6 DRB1*04:05/28/43/+ DRB1*13:02/36/65/+
TU7 DRB1*04:03/07/11/+ DRB1*08:03/10/29/+
TU8 DRB1*13:02/29/36 DRB1*16:02/05/10
TU9 DRB1*14:05:01 -
TU10 DRB1*09:01:02 DRB1*12:01/06/10/+
DNA sample ID PCR-SSOPAllele 1 Allele 2
TU1 DRB1*09:01/04/05 DRB1*15:01/13/16/+
TU2 DRB1*09:01/04/05/+ DRB1*14:05/23/43/+
TU3 DRB1*01:01/05/07/+ DRB1*14:05/23/45/+
TU4 DRB1*04:10 DRB1*14:01/26/54/+
TU5 DRB1*09:01/04/05 DRB1*13:02/96
TU6 DRB1*04:05/29/45/+ DRB1*13:02/73/96
TU7 DRB1*04:03/39/41/+ DRB1*08:03/23/27/+
TU8 DRB1*13:02/73/96 DRB1*16:02
TU9 DRB1*14:05/23/43/+ -
TU10 DRB1*09:01/04/05/+ DRB1*12:01/06/08/+
DNA sample ID SS-SBTAllele 1 Allele 2
TU1 DRB1*09:01:02:(01) DRB1*15:01:01:01/02/03
TU2 DRB1*09:01:02:(02) DRB1*14:05:01:(02)
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TU3 DRB1*01:01:01 DRB1*14:05:01:(02)
TU4 DRB1*04:10:(03):(01) DRB1*14:54:01:(02)
TU5 DRB1*09:01:02:(01) DRB1*13:02:01:(02)
TU6 DRB1*04:05:01:(01) DRB1*13:02:01:(02)
TU7 DRB1*04:03:01:(02) DRB1*08:03:02:(02)
TU8 DRB1*13:02:01:(02) DRB1*16:02:01:(02)
TU9 DRB1*14:05:01:(02) -
TU10 DRB1*09:01:02:(01) DRB1*12:01:01:(02)
Table 3. Results of HLA DNA typing for the HLA-DRB1 locus by the Sanger SBT, PCR-SSOP and NGS SS-SBT methods.
The / is possible ambiguity, + is more than the possible ambiguities indicated by /, parenthesis and bold letters
indicate tentative allele names, not yet officially approved by the WHO Nomenclature Committee. Blue background
indicates HLA alleles with ambiguous allele.
An average sequencing depth was 387.9 in total, ranging between a depth of 53.5 in TU7 of
HLA-DQB1 and 924.0 in TU4 of HLA-C. An example of the minimum and maximum depth
and ratio of depth between two allele sequence reads for HLA-C in five DNA samples using
the Roche GS Junior is shown in Table 4. The average depth ratio between haplotypes or alleles
of HLA-A, -B, -C, -DRB1 (mix 2), -DQB1 ranged from 0.6 to 1.6, suggesting a satisfactory allelic
balance was achieved with the PCR reactions. In comparison, the ratio of depth between two
alleles in the HLA-DRB1 (mix 1) sequences was more variable exceeding a ratio delta of 1.0,
which may be due to the marked difference in the sizes of PCR products among DRB1 groups
(6-11 kb). However, this ratio of depth between two alleles did not affect sequence determi‐
nation from the enhancer–promoter region to the exon 2 region of the DRB1 gene when the
number of draft reads was increased.
Depth
Allele Sample ID Read Num. Min Max Ave Ratio*
Allele 1
TU1 4,766 87 628 339.9 0.9
TU2 11,296 246 1,433 847.4 1.0
TU3 3,648 91 595 290.9 1.1
TU4 12,232 245 1,446 924.0 1.1
TU5 5,339 171 843 433.5 1.0
Allele 2
TU1 4,876 106 634 371.1 0.9
TU2 11,465 234 1,425 883.5 1.0
TU3 3,392 85 616 262.6 1.1
TU4 12,103 230 1,447 870.6 1.1
TU5 5,265 156 868 427.5 1.0
Table 4. Minimum and maximum depth and ratio of depth between two-allele sequence reads for HLA-C from five
DNA samples using the Roche GS Junior. *Ratio is the average depth of allele 1/average depth of allele 2.
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Overall, in this analysis, 21 HLA allele sequences were newly determined, 17 of them were
newly identified alleles and four were alleles extended from 2-digit to 8-digit level sequences.
Most of the newly identified SNPs and/or indels for 16 alleles were observed in the introns,
whereas a synonymous SNP was identified in one allele of DRB1*04:10:(03):(01)) (parenthesis
indicates tentative allele name, not yet officially approved by the WHO Nomenclature
Committee). A comparison of the alleles detected for HLA-DRB1 by Sanger-SBT and SS-SBT
in ten samples is shown in Table 3.
The HLA-DQA1, -DPA1 and -DPB1 alleles were assigned only at the 6-digit level of exon 2
with no novel alleles discovered in the 10 genomic DNA samples. This lower level assignment
was likely due in part to low SNP densities preventing the haplotype genomic segments to be
properly aligned and the phases separated from each other.
DRB3/4/5 sequences were identified to the field 4 level in both phases and validated by Sanger
sequencing [56]. An average depth of DRB3/4/5 was 277 in total (107 in TU1 to 561.7 in TU11.
The number of newly determined allele sequences at the field 4 level of resolution was two for
DRB3 (DRB3*01:01:02:(02) and DRB3*02:02:01:(03)), three for DRB4 (DRB4*01:03:01:(04),
DRB4*01:03:01:(05) and DRB4*01:03:01:(06)) and one for DRB5 (DRB5*01:01:01:(02)) (the allele
names at field 4 are tentative as they have not yet been officially approved by the WHO
Nomenclature Committee). Six allele sequences were extended from a field 2 or 3 level to a
field 4 level with one for DRB3 (DRB3*03:01:01:(01)), one for DRB4 (DRB4*01:03:02:(01)) and
two for DRB5 (DRB5*01:02:(01):(01) and DRB5*02:02:(01):(01)). Field 4 level haplotype struc‐
ture of DRB1-DRB3/4/5 were also determined by SS-SBT and reported by [56].
3.2.2.4. Sequencing multiplex LR-PCR generated libraries prepared for MGSR
Using the libraries prepared from pooled LR-PCR for MGSRs (Figure 5), we sequenced 81
Japanese and Caucasian genomic samples by the Roche GS Junior instrument and assigned
the aligned alleles across the entire gene regions of the eleven HLA gene loci without any
ambiguities at least to the field 3 assignment level. Of the 164 alleles detected at the field 4
assignment level, 78 (47.6%) were newly detected alleles. We were unable to determine the
allele sequences of HLA-DQA1, -DPA1 and -DPB1 at field 4 due to a lack of tag SNPs available
to identify and separate the two phases within some of the noncoding regions. However, all
the HLA exonic alleles were assigned without ambiguity at the field 3 level.
3.2.3. Sequence read information from the Ion PGM system
The amplicons amplified from eight HLA loci (A, B, C, DRB1, DQA1, DQB1, DPA1 and DPB1),
representing a total of 60 kb of the entire gene regions (from the enhancer-promoter region to
the 3’UT region), were prepared and pooled for the construction of barcoded DNA libraries
from four DNA samples (TU1, TU3, TU5 and TU8) that had been previously sequenced by the
Roche Junior system (Table 1). The four-barcoded samples were sequenced as a multiplex in
a single run on an Ion 316™ chip. Figure 6 shows the workflow of the SS-SBT method per‐
formed by the Ion PGM™ sequencer that completed the processes from sample preparation
to sequence analysis within three days. Previously, four days were needed for the manual
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sample preparation and library construction from the time of PCR amplification to HLA allele
definition [42]. Now, with the use of automated procedures, such as the AB Library Build‐
erTM system and Ion OneTouchTM system from Life Technologies, we have shortened the
workflow significantly to just two to three days.
The number of reads, number of bases, and median read-length of each sample are shown in
Table 5. A total of 522 Mb of sequence data was produced (about 600K to 720K reads per
sample) with a range between 123.3 Mb for TU1 and 141.6 Mb for TU5, with an overall average
read length of 197.3 bp. The median read length was about 214 bp, which was sufficient to
resolve the phase ambiguity in all of the samples that were tested. Draft read numbers in total
were 2,646,446 reads with a range of reads from 605,501 for TU1 to 721,499 reads for TU5 that
were high quality reads with QV ≥ 10 at an average QV of 19.2 in the high quality reads.
Figure 6. Improved workflow and time reduction to simplify the SS-SBT method using the Ion PGM
Sample ID Number of Number of Median
Reads Bases (Mbp) Read
Length (bp)
TU01 605,501 123.3 220
TU03 644,314 127.2 214
TU05 721,499 141.6 214
TU08 675,132 130.2 214
Total 2,646,446 Total 522.2 Ave. 214
Table 5. Number of reads, number of bases, and median read length of each of four samples using the Ion PGM
sequencer.
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Alleles of HLA class I genes obtained from the typing method using Ion PGM™ are shown in
Table 6. The 1,292,006 draft sequence reads (48.8% of the passed assembly reads) when
compared with the reference sequences using the GS Reference Mapper (Ver. 2.5) matched
consistently with the HLA alleles that were assigned by Roche GS Junior sequencing. The
average depth between two-allele sequence reads spanned from 581 for HLA-DRB1 in the TU1
sample to 2177 for HLA-B in the TU5 sample. The ratio between the average depth of allele 1
and average depth of allele 2 was 0.87 to 2.03. These typing results using the Ion PGM were
consistent with the results obtained by Roche Junior system at an 8-digit level with no phase
ambiguity. Also, for HLA class II genes, the Ion PGM typing results for HLA-DRB1, -DQA1,
-DQB1, -DPA1 and -DPB1 by the SS-SBT methods was an exact match with the results obtained
by Roche Junior system demonstrating that complete and correct HLA typing was carried out
efficiently by both sequencing systems [42].
A comparison between the Ion PGM and the Roche GS Junior for the depth distribution
obtained for HLA-B is shown in Figure 7.
The depth distribution of nucleotide calls across the HLA-B DNA sequence in different
samples occurred with numerous peaks and valleys. For HLA-B the depth of nucleotide calls
was lowest at a depth of 38 for allele 2 in sample TU01 where a string of polyG was sequenced
in intron 7 by the Ion PGM sequencer. However, a depth of > 30 appears to be sufficient for
accurate calls and a sequence run of more than 15 identical nucleotides seemed to be accurate
enough both by the Roche Junior and Ion PGM sequencers in this study. Overall, the trend in
the variation of depth distributions tended to be similar between the samples for both the
Roche GS Junior and Ion PGM suggesting that read depth was probably more dependent on
the gene sequence and grouping of nucleotides than other factors such as read length,
fragmentation of PCR products for the library construction, fragment size selection, emPCR
variability and efficiency of sequencing primer locations.
Locus Sample ID Allele 1 Allele 2
Allele name Depth Ave. Allele name Depth Ave.
HLA-A TU01 A*02:06:01:01 1281 A*11:01:01:01 1297
TU03 A*24:02:01:01 1171 A*31:01:02:01 1194
TU05 A*26:01:01:01 1922 A*31:01:02:01 1923
TU08 A*24:02:01:01 1280 A*332:03:01:01 1267
HLA-B TU01 B*40:02:01:01 1509 B*55:02:01(:02)* 1419
TU03 B*02:06:01:01 1337 B*35:01:01:02 1330
TU05 B*02:06:01:01 2167 B*35:01:01:02 2177
TU08 B*02:06:01:01 1478 B*48:01:01:01 1428
HLA-C TU01 C*02:06:01:01 1612 C*03:03:01:01 1576
TU03 C*02:06:01:01 1328 C*07:02:01:03 1296
TU05 C*02:06:01:01 1831 C*07:02:01:04 1808
TU08 C*02:06:01:01 1661 C*14:03:01:01 1642
Table 6. Class I alleles for each sample identified by typing with Ion PGM.
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3.3. HLA assignment software comparisons
We developed an in-house software system (SEABASS) for HLA sequence analysis, allele and
in phase haplotyping and compared it to two commercial software systems, the Conexio
Genomics genotyping software, Assign-MPS v1 [59], and the Omixon Target HLA Typing
software program [70]. The user interface for the Assign-MPS v1 is shown in Figure 8 for (A)
accurately genotyping the HLA-B*56:01:01(02) sequence and (B) not detecting DQB1*03:03:02
because of too many low quality sequence reads.
All three software systems imported and converted the.fna files (FASTA format sequence files
for each read) generated by the GS Junior or the Ion PGM software into the appropriate files
for HLA genotype assignments. All the software programs analysed the various sequence
reads, sorted them according to genomic primer and MID tag or barcodes, compared the
sequences to the IMGT/HLA sequence database and generated a consensus sequence with
allele assignment taking into account the exonic and intronic sequence and phase relationship.
The numbers of different reverse and forward reads for each amplicon were indicated, phased
and automatically assigned a genotype only if the aligned sequences were perfectly matched
with the alleles listed in the HLA sequence database (Figure 9). In cases where the aligned
sequence reads were mismatched at one or more bases with the database, manual editing
allowed for further investigation and assignment of a genotype.
Figure 7. Distribution of depth of base calls for all samples at each nucleotide position of the HLA-B gene using Ion
PGM and Roche GS Junior sequencers
A comparison of the three software systems for allele assignment in terms of platform,
convenience, analysis speed, detection of new alleles, field 2 and field 4 level of typing
assignment are shown in Table 7. All three software systems performed excellently for HLA
typing at the field 2 level, but the SEABASS method was better than Assign and Omixon for
HLA typing at the field 4 level. In addition, the SEABASS and Assign software could detect
new alleles whereas the Omixon did not provide this possibility. However, Omixon was best
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for analysis speed and convenience of use. Overall, there was marginal difference in the
efficiency, performance, analysis and outputs between the three output systems, although we
favored our in house system over the commercially available Conexio Genomics software on
a cost benefits basis.
SEABASS Omixon 1.6.0 Assign MPS
Platform Linux Mac/Windows Windows
Convenience * *** *
Analysis speed * *** **
Detection of NEW allele YES NO YES
Field 2 level typing *** ** **
Field 4 level typing *** * *
Table 7. Comparison of allele assignment software systems
4. Discussion
Our NGS study focused on developing a suitable SS-BT method for in phase HLA genotyping
for research and diagnostic laboratories using two of the commercially available low to
medium throughput capacity NGS systems, the Roche GS Junior and the Ion PGM [42,56]. So
far, in our best-case scenario, we were able to sequence 11 HLA loci for 5 individuals in a single
sequencing run by Roche GS Junior or the Ion PGM. We have not used the full capacity of the
Ion Torrents sequencing chip and, therefore, there is a potential to use a greater number of loci
or individual samples (at least 57 samples) than we have already used for a single sequencing
run. Moreover, both platforms provided high-resolution or super high resolution HLA typing
without ambiguities, depending on the LR-PCR design to amplify the HLA gene loci.
High-throughput HLA genotyping methodologies were previously developed using mas‐
sively parallel sequencing strategies, such as Roche/454 [36,37,40-42,56,71] and Illumina MiSeq
sequencing [43,72]. Most of these high-throughput HLA-genotyping studies amplified a few
individual exons (usually exons two, three and four) in an exon based strategy and sequenced
in a multiplexed manner. LR-PCR was used by a few of the investigators to amplify large
genomic regions of each gene including introns and all or most of the exons in a single PCR
[40,42,43,56,72]. We also chose to combine LR-PCR with NGS because LR-PCR requires only
one or two primer sets and eliminates the need to validate multiple sets of primers to amplify
all alleles in the exon-based strategy. In addition, the error rates of the polymerase enzymes
used in LR-PCR, because of error repair, are typically two- to six-fold lower than that of Taq
polymerase that is used in conventional PCR [73]. We amplified and sequenced from the 5’
promoter to the 3’ UTR including exons 1-7 for HLA class I and class II genes in order to
substantially improve the allele resolution for genotyping in comparison with the previous
conventional genotyping methods, such as SSOP and SBT, with which allele calling of
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Figure 8. Assign-MPS v1 user interface (A) accurately genotyping the HLA-B*56:01:01(02) sequence, and (B) not de‐
tecting DQB1*03:03:02 because of too many low quality sequence reads
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sequences was largely limited to exons 2 and 3 for HLA class I genes and exon 2 for HLA-
DRB1.
Figure 9. Omixon software system output viewer of HLA typing analysis results for HLA-A, -B, -C, -DPB1, -DQB1 and -
DRB1 at the field 2 level of allele resolution
We developed and tested LR-PCR for the following 11 class I and class II HLA genes, HLA-A,
-B. -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1 and -DPB1 using 13 separate LR-
PCRs. The entire gene sequence from the enhancer/promoter region to the 3’UTR-region was
amplified for all of the HLA gene loci, except for HLA-DRB1, -DPB1 and -DRB3/4/5. PCR of
HLA-DRB1 and -DPB1 was divided into two parts with enhancer/promoter to exon 2 and exon
2 to 3’UTR for HLA-DRB1, and enhancer/promoter to intron 2 and intron 1 to 3’UTR for
DRB1*15:01:01:03 because of the large size of intron 1 (~ 8kb) and/or the complexity of
nucleotide repeat (microsatellite) polymorphisms in intron 2 (Figure 7). The three DRB3/4/5
specific primer sets amplified the gene regions from intron 1 across to exon 6 and into the
3’UTR. The LR-PCR of these HLA genes revealed intronic as well as the exonic polymorphic
sites, which extended the HLA allelic resolution phase, but also provided important phasing
information to assist with the resolution of combination ambiguities and identifying previ‐
ously unknown alleles outside the regions of exon 2 and 3. Although the IMGT/HLA database
has sequences mostly of exons 2 and 3 [74,75], the promoter/enhancer, intron, and 3’UTR
variants should not be ignored for more comprehensive HLA typing now and into the future.
The genetic variants in a regulatory element such as promoter or even introns need to be
extensively analyzed because autoimmune [76] and infectious diseases [77] have been
associated with the differential expression levels of the HLA genes in different haplotypes [78].
In addition, null alleles resulting from intronic polymorphisms warrant investigation and
resolution to better understand their functional effects [79-82].
After PCR amplicon production, there are four main steps leading to sequencing and HLA
data analysis; amplicon library preparation, emulsion PCR, NGS and HLA data analysis
(Figure 2). The preparation of the template library is an important step because the PCR
amplicons are used either singly or pooled together into a multiplex and then labeled with
sequence tags (indexes, barcodes or MIDs) during library construction to facilitate sample
multiplexing prior to emulsion PCR and sequencing. The addition of different barcodes to
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different sample libraries enables the independent detection of sequences in a mixture of
different samples. Computing software is used to accurately parse the tagged sample files
during the analysis of sequencing data. However, a possible disadvantage of using too many
multiple barcoding tags is to lose sequencing depth because when samples are pooled for
multiplexing the amount of input DNA for each sample, due to the increased sample number,
is reduced.
In previous studies, most investigators using either the Roche or Illumina systems pooled their
PCR amplicons at equimolar concentrations for even gene distribution before constructing
barcoded libraries [36,37,40,41,43,56,71,72]. The ligation of barcodes to the fragmented DNA
templates during library construction allowed a varying number of different samples to be
sequenced during a single sequencing run, depending on read lengths, the capacity of the
sequencing platform and the number of pooled amplicons that were used. For example, Erlich
et al. [71] reported sequencing a maximum of 760 samples per run after loading a multiplex of
95-96 barcoded samples into a single lane of an 8-region PicoTiter Plate using the 454 Genome
Sequencer FLX instrument. Initially, we used only a single gene-sequencing run (SGSR) by
sequencing a single PCR amplicon and up to ten barcoded samples per sequencing run with
the Roche GS Junior and chose to use only up to four barcoded samples per sequencing run
with the Ion PGM [42]. As described in this chapter, we now have changed from SGSR to a
multiplex gene-sequencing run (MGSR), for which we pooled all 13 LR-PCR amplicons
together into a single sample (Figure 5) prior to constructing libraries for five barcoded samples
per sequencing run. This change, from SGSR to MGSR, reduced the number of sequencing
runs from 13 to 1, thereby greatly reducing the workload, the cost per sample and the overall
cost per individual. Currently, five barcoded samples using 13 LR-PCR amplicons in a single
sample is close to Roche GS Junior’s maximum sequencing capacity of 80 Mb of sequence reads
per run (assuming an average 100-bp read length) without compromising depth of coverage
and increasing sequencing or genotyping errors. A statistically adequate depth of sequence
coverage is essential to prevent alignment errors and minimize genotyping errors. In compar‐
ison, the Ion PGM 318 sequencing chip has far greater sequencing capacity of 1000 Mb
((assuming an average 200 bp read length) and potentially we could use the Ion PGM for
genotyping up to 57 barcoded samples using the 13 LR-PCR amplicons in a single sample, if
necessary. Although the sample number per sequencing run is low for the Roche GS Junior
compared to high capacity NGS platforms, often a small HLA typing laboratory for trans‐
plantation matching would require the typing results from only a small number of samples
on a weekly basis. If sequencing is required for a very large number of samples, such as for
association studies or population diversity studies, our workflow for the Roche Junior can be
easily adapted to the larger capacity platforms such as the Roche 454 Genome Sequencer FLX
instrument.
Apart from different sequencing capacities, the Roche Junior and Ion PGM use different
sequencing principles and procedures. Roche uses a pyrosequencing fluorescence technology
with a light output detected by camera scanning [31, 32], whereas the Ion PGM uses Ion Torrent
semiconductor sequencing technology with simple sequencing flow chemistry and no light
[33]. Ion PGM is the first commercial sequencing machine that does not require fluorescence
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and camera scanning, resulting in higher speed, lower cost, and smaller instrument size.
Currently, it enables 200 bp reads in 3 hours and the sample preparation time is less than 13
hours for 8 samples in parallel. Because every new sequencing technology introduces unique
errors and biases into the resulting DNA sequences, a proper understanding of the NGS
specific characteristics that are used to identify and interpret reads is crucial in assessing the
accuracy and applications for this new technology. Both manufacturers provide their own
unique software to processes the raw acquisition data and produce read files that contain high
quality consensus reads and draft assemblies. Roche has the GS analysis software and Ion
Torrent has a web browser driving the Torrent Suite Software on computers attached to their
respective sequencing instruments. For both platforms, we used the manufacturers software
to preprocess the DNA sequencing raw data before transferring the edited data onto our HLA
genotyping software. Therefore, we have not directly addressed what errors are introduced
into the raw reads by the NGS apparatus. However, others have shown that the major
sequencing errors with both sequencing instruments prior to pre-processing are largely related
to high frequency indel polymorphisms, homopolymeric regions, replicate bias, and substi‐
tution errors that mostly increase in rate with distance from the read start [45,65-67]. In
addition, the quality scores that are Phred-based can be only used to detect inserted and
substituted bases for both the Roche and Ion Torrent platforms. While the Ion PGM quality
scores underestimate the base accuracy, the Roche 454 quality scores tend to over estimate the
base accuracy [45,65-67]. Although there are no key studies of raw error reads directly
comparing the Roche GS Junior with Ion PGM outputs, a recent statistical study has concluded
that the accuracy of the Ion PGM is poorer than that of light-based technologies [65]. On the
other hand, direct comparisons of the Roche light-based technologies and Ion PGM of pre-
edited sequencing data of bacteria has generally concluded that there is little difference in the
accuracy of the sequencing data and that most errors arise with indel polymorphisms and
homopolymeric regions [45-47]. Currently, we are conducting our NGS sequencing experi‐
ments with 100 DNA samples using the Roche Junior and 200 DNA samples with the Ion PGM,
so, at this stage, we have not performed any accurate or meaningful statistical comparisons
for the various sequencing variables produced by the two different platforms. In general,
however, the indels and homopolymers are only a minor problem for SS-SBT HLA genotyping
by NGS using either of the two platforms.
After pre-editing the sequences generated by the two NGS platforms using the manufacturers
software, we transferred the edited data to HLA typing software. We compared a software
program, called the Suzuki method, which was developed in-house, against two commercial
programs, Omixon Target (Omixon) and Assign MPS (Conexio). These stand-alone software
programs were assessed and compared for in phase sequence alignment of HLA genes and
for allele assignment at different levels including the 8-digit level. Most genotype-calling
algorithms select the HLA type candidates based on optimized alignment to cDNA references
from the IMGT-HLA database due to the lack of genomic reference sequences. All three
software programs consolidated and assessed the various sequence reads, sorted them
according to genomic primer and barcodes, compared the sequences to the IMGT/HLA
sequence database references and generated a consensus sequence with allele assignment
taking into account the exonic and intronic sequence and phase relationship. The barcodes or
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MID tags identified by the software were used to reveal the reads of the various samples. Scores
for sequence measures and quality assurances were provided including sequence depth, allele
depth and allelic balance. Reads were aligned to the various loci and regions based on 100%
matching between the read sequence and the reference library. Finally, a consensus sequence
was generated and allele assignment made taking into account exonic and intronic sequence
as well as phase relationship. The numbers of different reverse and forward reads for each
amplicon were indicated, phased and automatically assigned a genotype only if the aligned
sequences were perfectly matched with the alleles of genomic references or constructed
references. A mapping procedure was applied for each candidate allele to verify the accuracy
of the HLA typing and to detect novel alleles. In cases of less than 100% match, even at 99%,
mis-mapping can occur among the HLA loci. Also, at least an average 30-fold depth was
necessary to identify genetic variants with high sensitivity and resolution. When sequencing
read numbers were too few, then we could not make exact assignments. If aligned sequence
reads were mismatched at one or more bases with the database, manual editing allowed for
further investigation and assignment of a genotype. Overall, there was little difference in the
efficiency, performance, analysis and outputs between the three software systems, although
we favored our in house program over the commercially available software on a cost benefits
basis. Because the IMGT/HLA sequence database has relatively few genomic sequences, at less
than 6% of the database entries, a major task remains to continue building a suitable reference
library for all the known polymorphic HLA genes.
Our main aim in using the NGS technology was to eliminate the ambiguities currently
associated with the conventional HLA genotyping methods. So far, we found that the SS-SBT
method is superior to other HLA DNA typing methods, especially to efficiently detect new
HLA alleles and null alleles at the 8-digit level of DNA typing without ambiguity. Although,
at most, only 100 Japanese and Caucasian genomic DNA samples were used in this study, we
unequivocally defined the HLA-A, -B, -C, -DRB1 and -DQB1 loci to single HLA alleles at the
8-digit level without any ambiguity. In addition, 17 DRB allele sequences, seven in DRB1, three
in DRB3, four in DRB4 and three in DRB5, were newly determined to the field 4 level of allele
resolution without phase ambiguity by SS-SBT. However, achieving a complete depth of
correct sequence information in most samples of DRB1 and in some samples of DRB3/4/5, such
as TU20 in DRB3, was compromised by the presence of microsatellites in a limited number of
intronic sites. Major sequence instabilities were encountered in our study with T5~17 and T2~27
mono-stretch sequences and GT7~28 and GA3~23 microsatellite repeats in intron 1 of DRB1, intron
5 of DRB1 and intron 2 of DRB1 and DRB3/4/5 alleles that were obtained in our study and from
the IMGT-HLA database. These instabilities within the microsatellite repeats are probably
compounded by PCR and sequencing errors [65], but could be solved by Sanger sequencing
of PCR products using high fidelity DNA polymerase.
All the allele sequences, excluding DRB1*09:21, were perfectly matched to at least the previ‐
ously reported field 1 or field 2 level of allele information [83]. Therefore, the newly designed
primers and PCR conditions for HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1 and -DPB1 [42]
and -DRB3/4/5 [56] are efficient for DNA typing by the SS-SBT method. Of the 164 alleles
detected at the field 4 assignment level in 81 Japanese and Caucasian samples, 78 (47.6%) were
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newly detected alleles. Therefore, simply increasing the sample size in future analyses of HLA
polymorphisms by the SS-SBT method could identify new non-synonymous substitutions
along with indels that generate a null allele. A new allele DRB1*09:21 that we identified in only
one sample so far, in comparison to the 129 DRB1*09:01 positive genomic DNA samples typed
by SS-SBT in the Japanese population, suggests that the new allele has extremely low frequency
in the Japanese.
We encountered problems with some microsatellite sequences, especially for DRB1*15:01:01:03
with the complexity of microsatellite polymorphisms in intron 2. In addition, the 8-digit level
HLA alleles could not be assigned in HLA-DQA1, -DPA1 and -DPB1 because the SNP and
indel densities to separate both of the phases were much lower than in the other HLA loci.
Resolution was difficult for phase ambiguities in the conserved sequences at HLA loci, such
as exon 3 in the HLA class II genes. Therefore, most HLA allele sequences are still unknown
at the 8-digit level. In this respect, collection of the 8-digit level reference sequences using HLA
homozygous DNA samples, haplotype extraction methods [84] or third generation sequencers
such as one molecule real time DNA sequencer PacBio RS [85,86] (Pacific Biosciences, Menlo
Park, CA) that provide a 3 kb read length on average are necessary for solving the current
genotyping problems to improve the SS-SBT method.
The collection of HLA allele sequences at the 8-digit level and the development of HLA allele
assignment programs are necessary to improve the SS-SBT method. The average depth of
HLA-A, -B and -C was stable with a ratio of ~1:1. However, in comparison, the average depth
of HLA-DRB1 for LR-PCR mix 2 and -DQB1 was less stable with ratios varying between 1:1
and 1: <2 [42]. Monitoring the depth ratio and potential allele dropout is important to detect
PCR bias due to unexpected variations in the primer sites. In cases where the depth ratio is
drastically changed such as 1:5 or more, the primer sets and/or PCR condition may have to be
modified. Nevertheless, the newly developed HLA DNA typing method SS-SBT [42] is
potentially applicable to the diagnostic laboratory once some of the minor problems described
above are solved in future.
Our study is the first direct comparison between the GS Junior and Ion PGM sequencing
platforms for HLA genotyping. Although we have as yet to maximize the potential capacity
of the Ion PGM to meet our theoretical expectation of sequencing the pooled PCR amplicons
for 11 gene loci using 57 barcoded samples, the Ion PGM seems to perform as well as or better
than Roche Junior on a number of fronts. However, it is difficult to choose between the two
platforms at this stage and further work and comparative analysis will need to be performed
before drawing a definite conclusion. Whereas there is little difference in overall performance
between the two platforms at this time, the new Ion Torrent 318 chip offers greater capacity
for more samples and more accurate reads with read lengths of 400 bp, for which we are
presently testing 300 samples. In addition, automation of library preparations and emPCR
amplification steps prior to sequencing has improved the overall turn around time from library
preparation to allele readouts from four days to two/three days with the sequencing step
performed overnight (Figure 2).
Development of better technologies to reduce the complication of the process and running
costs is also necessary before the SS-SBT method is introduced into the diagnostic laboratory.
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In a previous simulated test of the Ion Torrent PGM system in a clinical laboratory setting, we
needed four days for the manual sample preparation and library construction from the time
of PCR amplification to HLA allele definition [42]. However, with the use of automated
procedures such as the AB Library BuilderTM system and Ion OneTouchTM system from Life
Technologies we have shortened the workflow significantly to just two days with a running
cost of US $17 per locus per sample. In comparison, the workflow for the Roche Junior remains
at four days from the time of PCR amplification to HLA allele definition at a running cost of
US $40 per locus per sample. Also, a new protocol using the new Ion 318 chip with 32 barcodes
for 400 bp-read high sequencing quality has increased sequencing capacity and enabled
sequencing reads up to and beyond 400 bp [87]. Although we are at this moment testing the
new Ion Torrent protocols with the Ion 318 chip it looks likely to lead to further improvements
and further cost reductions. Therefore, a decrease in the running costs of NGS is expected to
soon be substantially better than those of the conventional HLA DNA typing methods.
Whereas we have tested the Roche Junior and Ion PGM NGS compact systems, the Illumina
MiSeq is another commercially available compact NGS [45]. The Illumina MiSeq sequencer
appears to compare well with Roche Junior and Ion PGM for HLA typing [43,72] and se‐
quencing other regions and targets of interest [45]. Other laboratories have favored the
Illumina MiSeq system and have published the workflows and results for HLA typing and
sequencing haplotypes to high resolution levels [43,72]. The Illumina MiSeq offers some
advantages over the Roche and Ion PGM such as low DNA input amount, the pair-end reads
(ie., fragments sequenced in both directions) to determine in phase alleles and possibly, a better
and more reliable resolution of substitutions and indels [46]. However, the Illumina MiSeq
may not perform as well for the middle reads of a 150 bp/200 bp sequence and the generated
reads may exhibit rapidly increasing error rates as the read length increases, resulting in lower
quality contig assemblies [46]. Also, the HLA DNA data analysis step appears to be a more
difficult process [43,72] than that for the Roche Junior and Ion PGM (unpublished data). In
cases where the phase of an allele is unresolved by the NGS system and HLA software other
approaches may help to resolve the allele ambiguity. For example, one promising approach is
to use DNA haplotype-specific extraction of the gene from the sample using a commercially
available extraction kit, such as the solid-phase, capture-based EZ1 HaploPrep kit from Qiagen
[88], and then resequencing the unresolved haplotype. The DNA haplotype-specific extraction
procedure can extract genomic regions of up to 50 kb of contiguous sequence without ampli‐
cation or concentration of the extracted DNA, and it has been used successfully to genotype
and haplotype HLA class I and class II genes [84, 89-93] including adjoining genes such as
HLA-B, MICA and HLA-C [89].
HLA in-phase genotyping is important for a variety of applications including for infectious
disease studies, transplantation, pharmacogenomics, autoimmune diseases, population
diversity and human evolution, and treatment of cancer pathology by vaccination. While we
used the genome from whole blood or from peripheral blood mononuclear cells for HLA in
phase-genotyping the analysis of HLA cDNA from cells and tissue (fresh or formalin fixed)
would also be of value [38,39]. In humans, the HLA-A, -B, and -C locus-specific gene expression
patterns were reported in the peripheral blood leukocytes, colon mucosa and larynx mucosa
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by real-time PCR [94]. Recently, we investigated the relationship between haplotypes and gene
expression levels of the class I genes by sequencing the genomic DNA of pigs using the Roche
Genome Sequencer 454 FLX and found that the sequence read numbers closely reflected the
gene expression levels in white blood cells [95]. The use of the NGS sequencing method in
human studies, similar to our MHC locus-specific expression analysis in pigs, could also
provide informative data in various biomedical studies on HLA gene expression, such as the
detection of expression levels among inter- and intra-populations, and among different tissues,
both before and after vaccination against pathogens.
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor
organ and marrow transplantation [2,96]. HLA typing also plays critical roles in donor and
recipient matching for embryonic (ES) or induced pluripotent stem (iPS) cell transplantation
therapy. Currently, an iPS cell bank project is under way, led by Kyoto University, with the
participation of one of the co-authors (HI) of this chapter. It was reported that when thirty iPS
cell lines that have different combinations of homozygous HLA-A, -B, and -DR are generated,
these iPS cells will have matched the three loci in 82.2% of the Japanese population. For fifty
iPS cell lines, the chance of a match increases to 90.7% in the Japanese population [97].
In addition to finding new polymorphisms within exons, the SS-SBT method can analyze
polymorphisms in introns, promoter, enhancer, and 3’-UTR regions that have largely remained
unexplored until now. By analyzing polymorphisms in the entire region of HLA genes, the
functional influence of those polymorphisms can be revealed in transplantation, diseases, and
adverse effects of medications. For example, it is expected that about one in a thousand people
have a null allele (deficient mutant that influences function or expression) in the HLA region.
Since null alleles have a profound influence on GVHD or transplant establishment, especially
in hematopoietic stem cell transplantation, the detection of null alleles is considered to be of
great clinical importance.
The SS-SBT method has been developed to obtain massive and accurate sequencing data easily
and cost effectively. Recently, the authors of a critical review of HLA typing by NGS [98]
pointed out that the Roche company will discontinue product support for the 454 sequencing
systems in 2016, implying that the Roche Junior sequencing platform will be phased out
commercially in the near future. However, almost all the materials and reagents required for
the Ion PGM™ system are available as kit products, and one Gb of sequencing data can be
obtained within 5 hours of running the protocols and data analysis. Up to fifty-seven samples
can be multiplexed and eight HLA gene loci analysed at an eight-digit level in a single run.
Compared to the Luminex beads method or the SBT method, the SS-SBT is more cost effective.
For these reasons, the Ion PGM™ sequencer is potentially the perfect sequencer for HLA
genotyping using the SS-SBT method. With an expected increase in throughput and the
development of an automated system in the future, we hope that Ion PGM™ will be even easier
to use for routine HLA genotyping.
In conclusion, we have developed procedures for massively parallel sequencing of multiplex
products that can be used for several benchtop sequencing platforms. We have obtained
sequences of sufficient high quality to permit accurate HLA in phase genotypes across the full-
length gene from the 5’ promoter/enhancer region to the 3’ UTR for most of the classical class
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I and class II genes. The use of sample tags or barcodes allows for optimization of second
generation sequencing technologies by pooling samples and sequencing multiple samples in
parallel for time- and cost-efficient workflows. We are currently working towards optimizing
the Ion PGM/SS-SBT method for HLA in phase genotyping for both the clinical diagnostic and
research laboratories.
Erratum
The software Assign MPS 1.0 used in this study was a beta version and still under develop‐
ment at the time of publishing the chapter and not available commercially from Conexio.
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